Raphas Co., Ltd.
Financials
Valuation Metrics
Raphas Co., Ltd.'s Market Cap is ₩800B. At end of 2025 it was ₩1169B. Ranked #1387 of 2,436 in KR market (top 57%), #779 of 1,649 on KOSDAQ (top 47%), #31 of 57 in Household & Personal Products (top 54%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 80.03B KRW | KR#1,387/2,436 Sec#31/57 |
| Revenue | 30.69B KRW | KR#2,020/2,436 Sec#45/57 |
| Net Income | -4.32B KRW | KR—/2,436 Sec—/57 |
| Total Assets | 72.26B KRW | KR#1,971/2,436 Sec#41/57 |
| Net Assets | 29.85B KRW | KR#2,166/2,436 Sec#50/57 |
| Employees | 100 | KR#1,623/2,436 Sec#35/57 |
| Value | ||
| P/B | 2.68x | KR#2,069/2,436 Sec#47/57 |
| P/S | 2.61x | KR#1,957/2,436 Sec#50/57 |
| FCF Yield | 1.03% | KR#1,138/2,436 Sec#33/57 |
| Profitability | ||
| ROE | -14.48% | KR#1,983/2,436 Sec#47/57 |
| ROA | -5.98% | KR#1,940/2,436 Sec#44/57 |
| Op. Margin | -9.34% | KR#1,963/2,436 Sec#48/57 |
| Revenue Growth | -4.21% | KR#1,665/2,436 Sec#41/57 |
| Earnings Growth | -239.23% | KR#1,527/2,436 Sec#35/57 |
| Financial Health | ||
| Debt Ratio | 242.07% | KR#1,967/2,436 Sec#51/57 |
| Total Debt | 41.36B KRW | KR#1,054/2,436 Sec#19/57 |
| FCF | 828.0M KRW | KR#1,157/2,436 Sec#30/57 |
| Cash | 9.15B KRW | KR#1,720/2,436 Sec#33/57 |
| Current Ratio | 0.83x | KR#2,015/2,436 Sec#47/57 |
| Performance | ||
| 1Y Return | -37.05% | KR#1,761/2,436 Sec#37/57 |
| 1M Return | 6.53% | KR#398/2,436 Sec#21/57 |
| From 52W High | -46.19% | KR#1,024/2,436 Sec#32/57 |
| 1Y MDD | -67.90% | KR#1,846/2,436 Sec#44/57 |
| Trading | ||
| Volume | 8,780 shares | KR#2,151/2,436 Sec#51/57 |
| Foreign Own. | 0.00% | KR—/2,436 Sec—/57 |
| Per Share | ||
| EPS | -455 KRW | KR—/2,436 Sec—/57 |
| BPS | 3,272 KRW | KR#1,754/2,436 Sec#40/57 |
Company Info
Raphas, established in 2006 and headquartered in Gangseo-gu, Seoul, was listed on KOSDAQ as a technology growth company in 2019. It specializes in the research, development, manufacturing, and sales of soluble microneedle patches, a transdermal drug delivery technology. While current sales are primarily in cosmetic fields like beauty patches, the company is expanding its business into pharmaceuticals, vaccine patches, and medical devices. Its unique DEN technology allows for microneedle production in about 5 minutes using only room-temperature air circulation, without UV light, and offers flexible control over length and pattern without molds.